Research programme: tocotrienols - LipoGenicsAlternative Names: Tocotrienols - LipoGenics
Latest Information Update: 24 Apr 2007
At a glance
- Originator LipoGenics
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Benign prostatic hyperplasia
Most Recent Events
- 24 Apr 2007 Discontinued - Preclinical for Benign prostatic hyperplasia in USA (unspecified route)
- 01 Mar 2001 Preclinical development for Benign prostatic hyperplasia in USA (Unknown route)